Annals of the New York Academy of Sciences Publishes Thymosin Beta 4 Research Papers
25 Maio 2010 - 9:30AM
Business Wire
RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN)
announced today that nineteen research and clinical papers on
thymosin beta 4 (Tβ4) have been published in the May 2010 issue of
the Annals of the New York Academy of Sciences, volume 1194.
Preliminary research and clinical data were presented at the “2nd
International Symposium on Thymosins in Health and Disease” in
September, 2009.
The publications relate to the biological activities and
mechanisms of action of Tβ4; preclinical studies of Tβ4 in tissue
repair and regeneration; Tβ4-induced cardiac revascularization and
repair; treatment of stroke with Tβ4; and prevention of
myofibroblast infiltration in dermal wounds. Additional published
data were related to the potential tumor suppressive function of
Tβ4 in multiple myeloma. Clinical data from studies in the U.S. and
Europe were also included in the publication.
The scientific teams conducting the research represent a number
of institutions, including the U.S. Army Medical Research Institute
of Chemical Defense in Aberdeen, MD; the University of Texas,
Southwestern Medical Center in Dallas, TX; Ludwig Maximillians
University, Munich, Germany; the National Institutes of Health in
Bethesda, MD; UCL Institute of Child Health in London, England; the
Henry Ford Health Systems in Detroit, MI; the Pennsylvania State
University College of Medicine in Hershey, PA; the CHU University
of Liège in Liège, Belgium; the Universiteit Brussel in Brussels,
Belgium; the Wayne State University School of Medicine, Kresge Eye
Institute, Children’s Hospital of Michigan and William Beaumont
Hospital in Detroit, MI; Istituto Dermopatico dell ‘Immacolata in
Rome, Italy; and Vanderbilt University School of Medicine in
Nashville, TN.
About RegeneRx
Biopharmaceuticals, Inc.
RegeneRx is focused on the development of a novel therapeutic
peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection,
repair and regeneration. Currently, RegeneRx has formulated three
product candidates in clinical development: RGN-352, an injectable
formulation for systemic delivery to treat cardiovascular diseases,
central nervous system diseases, and other medical indications that
require administration by injection, that has completed a Phase 1
clinical trial; RGN-259, a sterile, preservative-free topical eye
drop for ophthalmic indications that is currently being supported
in compassionate use studies; and RGN-137, a topically applied gel
for chronic dermal wounds and reduction of scar tissue that is
currently in a Phase 2 clinical trial for the treatment of
epidermolysis bullosa. RegeneRx is initially targeting RGN-352 for
the treatment of patients who have suffered an acute myocardial
infarction, or heart attack, although recent animal research
suggests that this formulation may also benefit patients with
multiple sclerosis and stroke. RegeneRx has a fourth product
candidate, RGN-457, which is an inhaled formulation targeting
cystic fibrosis and other pulmonary diseases, in pre-clinical
development. These product candidates are based on Tβ4, a synthetic
copy of a 43-amino acid, naturally-occurring peptide that is the
subject of an exclusive worldwide license from the National
Institutes of Health. In addition to the four pharmaceutical
product candidates described above, RegeneRx is pursuing the
commercial development of peptide fragments of Tβ4 for potential
cosmeceutical use. RegeneRx holds over 60 worldwide patents and
patent applications related to its product candidates.
Forward-Looking
Statements
Any statements in this press release that are not historical
facts are forward-looking statements made under the provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve risks and uncertainties that
could cause actual results to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. You are urged to consider
statements that include the words “project,” “believe,”
“anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,”
“would,” “could,” “will,” ”may,” “potential” or the negative of
those words or other similar expressions words to be uncertain and
forward-looking. Factors that may cause actual results to differ
materially from any future results expressed or implied by any
forward-looking statements include the risks and uncertainties
inherent in our business, including, without limitation the risk
that our product candidates do not demonstrate safety and/or
efficacy in future clinical trials; risks related to our ability to
obtain financing to support our operations on commercially
reasonable terms; the progress, timing or success of our clinical
trials; difficulties or delays in development, testing, obtaining
regulatory approval for producing and marketing our product
candidates; regulatory developments; the size and growth potential
of the markets for our product candidates and our ability to serve
those markets; the scope and validity of patent protection for our
product candidates; competition from other pharmaceutical or
biotechnology companies; and other risks described in the Company’s
filings with the Securities and Exchange Commission (“SEC”),
including those identified in the “Risk Factors” sections of the
annual report on Form 10-K for the year ended December 31, 2009,
filed with the SEC on March 31, 2009, [and the quarterly report on
Form 10-Q for the quarter ended March 31, 2010, filed with the SEC
on May 17, 2010,] as well as other filings it makes with the SEC.
Any forward-looking statements in this press release represent the
Company’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
The Company anticipates that subsequent events and developments may
cause its views to change, and the Company specifically disclaims
any obligation to update this information, as a result of future
events or otherwise, except as required by applicable law.
Regenerx Biopharm In (AMEX:RGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Regenerx Biopharm In (AMEX:RGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
